February 21, 2018
Cytokinetics is currently conducting a Phase 2 clinical trial of CK-2127107 – now referred to by the generic name, reldesemtiv – which is designed to assess the investigational agent’s effect on multiple measures of muscle function in both ambulatory and non-ambulatory...
February 14, 2018
Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA.
Dear Members of the SMA community,
This past December marked one year since the FDA approval of SPINRAZA® (nusinersen), the first and only treatment...
February 9, 2018
The winter 2018 issue of Compass is now available online.
This issue covers Cure SMA’s community survey, and reviews how data is used to improve research, care and coverage in the SMA...